PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.77%
Negative revenue growth while MRVL stands at 1.55%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-7.59%
Negative gross profit growth while MRVL is at 1.76%. Joel Greenblatt would examine cost competitiveness or demand decline.
-25.49%
Negative EBIT growth while MRVL is at 1.27%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-26.18%
Negative operating income growth while MRVL is at 1.27%. Joel Greenblatt would press for urgent turnaround measures.
-29.30%
Negative net income growth while MRVL stands at 0.46%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-29.11%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-28.57%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-0.43%
Share reduction while MRVL is at 2.72%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
0.42%
Diluted share reduction more than 1.5x MRVL's 3.72%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
0.43%
Dividend growth of 0.43% while MRVL is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
-58.05%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-65.34%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
103.42%
10Y revenue/share CAGR under 50% of MRVL's 736.89%. Michael Burry would suspect a lasting competitive disadvantage.
38.18%
5Y revenue/share CAGR under 50% of MRVL's 104.05%. Michael Burry would suspect a significant competitive gap or product weakness.
17.88%
3Y revenue/share CAGR at 75-90% of MRVL's 23.48%. Bill Ackman would expect new product strategies to close the gap.
557.38%
10Y OCF/share CAGR under 50% of MRVL's 2041.57%. Michael Burry would worry about a persistent underperformance in cash creation.
25.82%
Below 50% of MRVL's 222.70%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
-8.46%
Negative 3Y OCF/share CAGR while MRVL stands at 332.41%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
339.00%
Below 50% of MRVL's 2787.12%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
54.62%
Below 50% of MRVL's 181.77%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
14.40%
Below 50% of MRVL's 456.99%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
23.29%
Below 50% of MRVL's 9943.30%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
27.79%
Below 50% of MRVL's 58.40%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
21.98%
3Y equity/share CAGR at 50-75% of MRVL's 33.72%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
526.91%
Dividend/share CAGR of 526.91% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
332.92%
Dividend/share CAGR of 332.92% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
30.81%
3Y dividend/share CAGR of 30.81% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
3.29%
AR growth is negative/stable vs. MRVL's 25.76%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
10.39%
We show growth while MRVL is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-0.68%
Negative asset growth while MRVL invests at 5.99%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
1.75%
Under 50% of MRVL's 3.56%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
No Data
No Data available this quarter, please select a different quarter.
7.65%
R&D growth drastically higher vs. MRVL's 2.86%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
1.54%
SG&A declining or stable vs. MRVL's 3.15%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.